Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males



Status:Completed
Conditions:Colorectal Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Women's Studies, Dermatology
Therapuetic Areas:Dermatology / Plastic Surgery, Oncology, Reproductive
Healthy:No
Age Range:13 - 26
Updated:5/10/2018
Start Date:June 28, 2011
End Date:December 12, 2017

Use our guide to learn which trials are right for you!

AMC-072: Protective Effect of Quadrivalent Vaccine in Young HIV-Positive Males Who Have Sex With Males

RATIONALE: Vaccines made from a gene-modified virus may help the body build an effective
immune response to prevent viral infection.

PURPOSE: This phase II trial is studying how well vaccine therapy works in preventing human
papillomavirus (HPV) infection in young HIV-positive male patients who have sex with males.

OBJECTIVES:

Primary

- To determine the protective effect of the HPV-6, -11, -16, -18 vaccine in preventing
penile/scrotal condyloma and HPV-6, -11, -16, -18- associated perianal/anal disease in
HIV-positive males who have sex with males (MSM) age 13-26 years by comparing the
incidence of these lesions among those naïve to the relevant HPV type(s) at baseline to
those who are not naïve at baseline.

- To determine the protective effect of the HPV-6, -11, -16, -18 vaccine in preventing
persistent anogenital infection with HPV-6, -11, -16, or 18 in HIV-positive MSM age
13-26 years by comparing the incidence of persistent infection among those naïve to the
relevant HPV type(s) at baseline to those who are not naïve at baseline.

- To determine the protective effect of the HPV-6, -11, -16, -18 vaccine in preventing
anogenital lesions associated with HPV 6,-11,-16, -18 and persistent infection with
these types, in HIV-positive MSM age 13-26 years by comparing the incidence of lesions
and persistent infection among those naïve to the relevant types at baseline to incident
lesions and infection among MSM naïve to these HPV types who participated in the Merck
020 protocol and who received placebo as part of the protocol.

Secondary

- To define the safety of the HPV-6, -11, -16, -18 vaccine in HIV-positive MSM age 13-26
years.

- To evaluate the levels and persistence of HPV 6, 11, 16 and 18 Ab titers after the
vaccination series among subjects who are seropositive and seronegative at baseline.

- To examine whether the protective effect and antibody titers vary as a function of the
following at the time of initial vaccination: subject age, HAART treatment status, HIV
viral load, CD4 + T-cell count, and nadir CD4 level.

Tertiary

- To quantify anogenital HPV DNA viral load prior to and after receipt of the quadrivalent
HPV vaccine.

- To identify and quantify HPV types in the oral cavity of HIV-positive MSM prior to and
after receipt of the quadrivalent HPV vaccine.

- To identify HPV strain variants among HIV-positive participants prior to and after
receipt of the quadrivalent HPV vaccine.

- Assess the prevalence and incidence of urinary and gonorrhea and Chlamydia trachomatis
infection at baseline and their relationship with prevalent and incident anogenital HPV
infection and anal condyloma or AIN.

- To characterize young men's risk perceptions, sexual behaviors, and STI diagnosis after
HPV vaccination.

OUTLINE: This is a multicenter study.

Patients receive quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant
vaccine intramuscularly on day 1 and in weeks 8 and 24.

Blood and tissue samples may be collected periodically for laboratory studies.

After completion of study treatment, patients are followed up for 2 years.

DISEASE CHARACTERISTICS:

- Men with a history of at least one male sexual partner

- "Men" is defined as those documented "male" at birth (including male-to-female
transgendered persons)

- HIV-1 infection as documented by any federally approved, licensed HIV test performed
in conjunction with screening (ELISA, western blot, or other approved test)

- Alternatively, this documentation may include a record that another physician has
documented that the patient has HIV based on prior ELISA and western blot, or
other approved diagnostic tests

- Meets one of the following sets of criteria:

- Patients receiving antiretroviral therapy:

- Receipt of antiretroviral therapy for at least 3 months prior to entry

- No change in antiretroviral therapy within 30 days prior to entry

- Patients not receiving antiretroviral therapy:

- CD4-cell count ≥ 350 cells/mm³ within 90 days prior to study entry

- No plans to start antiretroviral therapy prior to Week 28

- Normal anal cytological result, LSIL/condyloma, or ASCUS result within 90 days prior
to entry, and no HGAIN on biopsy

- No current or history of anal or peri-anal carcinoma

- No anal cytological result of HSIL, atypical squamous cells suggestive of HSIL
(ASC-H), or suggestive of invasive carcinoma at screening; or history of these
results

- No presence of penile or scrotal condyloma, LGAIN (condyloma or AIN 1), HGAIN (e.g.,
AIN 2 or 3, or perianal intraepithelial neoplasia grade 2 or 3), or invasive carcinoma
at pre-entry on biopsy

- No history of HGAIN

PATIENT CHARACTERISTICS:

- Karnofsky performance score ≥ 70 within 45 days prior to entry

- Absolute neutrophil count (ANC) > 750 cells/mm^3

- Hemoglobin ≥ 9.0 g/dL

- Platelet count ≥ 100,000/mm^3

- AST (SGOT), ALT (SGPT) ≤ 3 times upper limit of normal (ULN)

- Total or conjugated (direct) bilirubin ≤ 2.5 times ULN within 45 days before study
entry, with the exception of isolated hyperbilirubinemia that is considered due to
atazanavir

- Calculated creatinine clearance ≥ 60 mL/min

- No hemophilia

- No active drug or alcohol use or dependence that, in the opinion of the site
Investigator, would interfere with adherence to study requirements

- No serious illness requiring systemic treatment and/or hospitalization within 45 days
prior to entry

- No serious medical or psychiatric illness that, in the opinion of the site
Investigator, will interfere with the ability of the subject to give informed consent
or adhere to the protocol

- No allergy to yeast or any of the components of Gardasil

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No prior splenectomy

- No prior receipt of Gardasil or other HPV vaccine

- No use of any systemic antineoplastic or immunomodulatory treatment, systemic
corticosteroids for greater than 14 days, investigational vaccines, interleukins,
interferons, growth factors, or IVIG within 45 days prior to study entry

- No expected use of any systemic antineoplastic or immunomodulatory treatment, systemic
corticosteroids used for greater than 14 days, investigational vaccines, interleukins,
interferons, growth factors, or IVIG during study followup

- No patients with hepatitis C who expect to initiate treatment for hepatitis C
(e.g., interferons) during this trial

- Not currently receiving anticoagulation therapy other than acetylsalicylic acid
We found this trial at
18
sites
4650 Sunset Blvd
Los Angeles, California 90027
 (323) 660-2450
Childrens Hospital Los Angeles Children's Hospital Los Angeles is a 501(c)(3) nonprofit hospital for pediatric...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
3550 Jerome Avenue
Bronx, New York 10467
(718) 920-4321
Montefiore Medical Center As the academic medical center and University Hospital for Albert Einstein College...
?
mi
from
Bronx, NY
Click here to add this to my saved trials
3550 Jerome Avenue
Bronx, New York 10467
(718) 920-4321
Montefiore Medical Center As the academic medical center and University Hospital for Albert Einstein College...
?
mi
from
Bronx, NY
Click here to add this to my saved trials
1600 Divisadero Street
San Francisco, California 94115
888.689.8273
UCSF Helen Diller Family Comprehensive Cancer Center UCSF’s long tradition of excellence in cancer research...
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
?
mi
from
Aurora, CO
Click here to add this to my saved trials
72 East Concord St.
Boston, Massachusetts 02118
617-638-4173
Boston University Cancer Research Center
?
mi
from
Boston, MA
Click here to add this to my saved trials
Boston, Massachusetts 02215
?
mi
from
Boston, MA
Click here to add this to my saved trials
1969 W Ogden Ave
Chicago, Illinois 60612
(312) 864-6000
John H. Stroger, Jr. Hospital of Cook County The Level 1 Trauma Center is one...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
Houston, Texas 77009
?
mi
from
Houston, TX
Click here to add this to my saved trials
La Jolla, California 92093
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Memphis, Tennessee 38105
?
mi
from
Memphis, TN
Click here to add this to my saved trials
New York, New York 10011
?
mi
from
New York, NY
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
?
mi
from
San Juan,
Click here to add this to my saved trials
Seattle, Washington 98101
(888) 862-2737
Virginia Mason Medical Center Established in 1920, Virginia Mason began as an 80-bed hospital with...
?
mi
from
Seattle, WA
Click here to add this to my saved trials